Perspective Therapeutics (NYSEAMERICAN:CATX) Director Robert Williamson III Buys 25,000 Shares of Stock

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) Director Robert Williamson III acquired 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 17th. The stock was purchased at an average cost of $0.84 per share, with a total value of $21,000.00. Following the transaction, the director owned 53,473 shares in the company, valued at approximately $44,917.32. This trade represents a 87.80% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Perspective Therapeutics Stock Down 6.9%

Perspective Therapeutics stock opened at $0.86 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18. The company’s 50-day moving average is $2.02 and its 200-day moving average is $3.42. Perspective Therapeutics, Inc. has a fifty-two week low of $0.78 and a fifty-two week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. On average, analysts anticipate that Perspective Therapeutics, Inc. will post -1.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CATX has been the topic of several research analyst reports. Royal Bank Of Canada lowered Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price objective for the company from $14.00 to $4.00 in a research note on Monday, October 26th. BTIG Research reaffirmed a “buy” rating on shares of Perspective Therapeutics in a research report on Monday, October 26th. Bank of America reduced their target price on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Friday, August 14th. Wedbush reissued an “outperform” rating and set a $7.00 target price (down from $9.00) on shares of Perspective Therapeutics in a report on Tuesday, November 10th. Finally, Piper Sandler dropped their price target on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Nine analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $10.10.

Read Our Latest Stock Analysis on CATX

Institutional Trading of Perspective Therapeutics

Hedge funds have recently modified their holdings of the stock. Commodore Capital LP bought a new stake in shares of Perspective Therapeutics during the 1st quarter worth about $26,424,000. Avidity Partners Management LP grew its stake in Perspective Therapeutics by 88.4% in the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after buying an additional 2,839,266 shares during the last quarter. Affinity Asset Advisors LLC grew its stake in Perspective Therapeutics by 954.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock valued at $13,196,000 after buying an additional 2,864,582 shares during the last quarter. Spruce Street Capital LP bought a new position in Perspective Therapeutics in the 1st quarter valued at about $10,955,000. Finally, Nantahala Capital Management LLC raised its holdings in Perspective Therapeutics by 7.2% in the 3rd quarter. Nantahala Capital Management LLC now owns 2,492,642 shares of the company’s stock valued at $6,855,000 after acquiring an additional 167,192 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

(Get Free Report)

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.

Further Reading

Insider Buying and Selling by Quarter for Perspective Therapeutics (NYSEAMERICAN:CATX)

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.